{"id":"gatifloxacin-combined-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Tendinopathy/tendon rupture"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:04:56.642303","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fourth-generation fluoroquinolone, gatifloxacin binds to and inhibits bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity. When used in a combined regimen, gatifloxacin is typically paired with other antimicrobial agents to broaden spectrum coverage and reduce resistance development.","oneSentence":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:45.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT00216385","phase":"PHASE3","title":"A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Institut de Recherche pour le Developpement","startDate":"2005-01","conditions":"Tuberculosis","enrollment":2070}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2006 Jun","pmid":"16647126","title":"Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone.","journal":"Ophthalmology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gatifloxacin combined regimen","genericName":"Gatifloxacin combined regimen","companyName":"Institut de Recherche pour le Developpement","companyId":"institut-de-recherche-pour-le-developpement","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial infections (likely respiratory, urinary tract, or other systemic infections in a combined regimen context).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}